Search

Displaying results 4011 - 4020 of 10000 in total
  1. Drug

    AI-850

    go.drugbank.com/drugs/DB05842
    Experimental

    AI-850 is a Cremophor(R)-free formulation of paclitaxel, the active ingredient in Taxol(R), a product used to treat a variety of solid tumors.

  2. Drug

    Dolasetron

    go.drugbank.com/drugs/DB00757
    ApprovedInvestigational

    Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. … Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative

  3. Drug

    Potassium triiodide

    go.drugbank.com/drugs/DB14492
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    DPI-221

    go.drugbank.com/drugs/DB06121
    Experimental

    DPI-221 is an investigational drug and a selective agonist for the δ-opioid receptor.

    Synonyms: .-((2S,5R)-2,5-DIMETHYL-4-(3-FLUOROBENZYL)-1-PIPERAZINYL)BENZYL)-N,N-DIETHYLBENZAMIDE, BENZAMIDE, N,N-DIETHYL-4-((S)-((2S,5R)-4-((3-FLUOROPHENYL)METHYL)-2,5-DIMETHYL-1-PIPERAZINYL)PHENYLMETHYL)-
  5. Drug

    Efalizumab

    go.drugbank.com/drugs/DB00095
    ApprovedWithdrawn

    The FDA approved efalizumab in 2003. It was later withdrawn in 2009 due to a potential risk of progressive multifocal leukoencephalopathy (PML).[L43797] … Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin.

  6. Drug

    T611

    go.drugbank.com/drugs/DB06391
    Experimental

    T611 is an investigational oral anti-cytomegalovirus (CMV) drug candidate.

  7. Drug

    MB-07803

    go.drugbank.com/drugs/DB05053
    Investigational

    MB07803 is a second generation gluconeogenesis inhibitor for the treatment of type 2 diabetes. It is designed to block the metabolic pathway in the liver that is responsible for producing glucose.

  8. Drug

    LY2275796

    go.drugbank.com/drugs/DB05165
    Investigational

    LY2275796 targets eukaryotic initiation factor- 4E (eIF-4E), a protein involved in the translation of key growth and survival factors that drive tumor progression, angiogenesis and metastases. … LY2275796 is a second-generation antisense anti-cancer drug candidate for clinical development.

  9. Drug

    Carbinoxamine

    go.drugbank.com/drugs/DB00748
    Approved

    The product label for carbinoxamine as an over the counter cough and cold medicine is being modified to state "do not use" in children under 4 years of age in order to prevent and reduce misuse, as many … unapproved carbinoxamine-containing preparations contained inappropriate labeling, which promoted unapproved uses (including management of congestion, cough, the common cold, and the use in children under

  10. Drug

    Cimicoxib

    go.drugbank.com/drugs/DB05095
    Investigational

    If approved, Cimicoxib would be the first drug in decades to treat depression by a new mechanism of action. … Cimicoxib is a selective COX-2 inhibitor being developed by Affectis as a treatment for depression and schizophrenia.